News
VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME, French equity savings plan for the financing of SMEs) (Paris:ALVAL), a Research & Development company committed to scientific innovation
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego)
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego)
Madvertise - Appointment of Andrew Vile for US rollout of the Madvertise and SYNC offer
Press Release
Paris, 9 February 2021 – 6 pm
Appointment of Andrew Vile for US rollout
of the Madvertise and SYNC offer
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French AdTech company
STREAMWIDE : 2020 REVENUE: EUR 14m (up 37%) - ANOTHER YEAR OF GROWTH FUELLED BY THE PLATFORMS BUSINESS (UP 67%)
_ STREAMWIDE (FR0010528059 – ALSTW – eligible for French PEA-PME), expert in
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
DOLFINES (EX DIETSWELL) : DOLFINES: Issuance of a 1.5 million euros Green Bond
PRESS RELEASE Paris, February 3, 2021
·With the issuance of a Green Bond of € 1.5 million, DOLFINES strengthens its capacity to contribute to the ecological transition
·Oil &
MND : First in Georgia: the Gudauri ski resort operates their new Remote Avalanche Control Systems thanks to MND SAFETY
MND, n°1 worldwide in avalanche risk prevention and control via its business line MND SAFETY, with its Georgian partner Mountain Resorts Solutions (MRS) have deployed the first ever avalanche risk
GROUPE LDLC : 2020-2021 NINE-MONTH REVENUES UP 45.5% TO EUR 542.1M
- Q3 REVENUES UP 51.3% TO €227.8M (UP 27.1% LIKE FOR LIKE)
- VERY STRONG GROWTH MOMENTUM IN ALL BUSINESSES
- 2020-2021 TARGETS REVISED UPWARDS: REVENUES OF AROUND €700M WITH EBITDA CLOSE TO €60M
MND : Opening of the new attraction in the heart of the Canton Tower: MND reinvents urban leisure activities
It is in the heart of the famous and vertiginous Canton Tower in China, one of the most spectacular buildings in the world due to its architecture and its hyperboloid structure, 600 meters high
PRISMAFLEX INTERNATIONAL : Continuing impact of the Covid-19 health crisis on Q3 2020-21 sales
Significant points:
- Q3 sales slightly up on Q2 figures.
- Upturn in Printing activity undermined by new restrictive measures imposed at the end of the year due to the health crisis.
- Hardware
GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS AND ANNOUNCES ITS CASH POSITION AS OF 31 DECEMBER 2020
IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug
GenSight Biologics Announces its 2021 Financial Calendar
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Median Technologies Records a 51 % Increase of Its 2020 Annual Revenue (Unaudited Figures)
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT) today announces strong business activity for the full year 2020 (unaudited figures). In 2020, despite the Covid-19 pandemic and global
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
VALBIOTIS kündigt Teilnahme an der 39. jährlichen J.P. Morgan Healthcare Conference und der H.C. Wainwright BioConnect vom 11. bis 14. Januar 2021 im virtuellen Format an
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
VALBIOTIS Announces Its Participation in the 39th J.P. Morgan Healthcare Annual Conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in Virtual Format
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating
EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
DOLFINES (EX DIETSWELL) : Success of the new private Placement of DOLFINES
PRESS RELEASE Paris, January 7, 2021
With the new success of a Private Placement with European investors, DOLFINES continues to strengthen its industrial and commercial capacity
DOLFINES, an
Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Median Technologies: Financial Communications Schedule for the First Half of 2021
Regulatory News:
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® announces the publication date for its 2020 results:
Publication
Date
2020 results
April 8
Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
PRISMAFLEX INTERNATIONAL : Evolution in the capital standing for Anthem Displays
Prismaflex partner up with Circle Graphics and maintain a minority holding via their Prismaflex USA subsidiary of 28.91%.
Prismaflex International announce they have concluded an association